Patterns of Cyanide Antidote Use Since Regulatory Approval of Hydroxocobalamin in the United States

被引:5
|
作者
Streitz, Matthew J. [1 ]
Bebarta, Vikhyat S. [2 ]
Borys, Douglas J. [3 ]
Morgan, David L. [4 ]
机构
[1] San Antonio Mil Med Ctr, Dept Obstet & Gynecol, San Antonio, TX 78261 USA
[2] San Antonio Mil Med Ctr, Dept Emergency Med, Dept Med Toxicol Serv, San Antonio, TX 78261 USA
[3] Concordia Univ, Sch Pharm, Dept Emergency Med, Mequon, WI USA
[4] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Scott & White Hosp, Temple, TX 76508 USA
关键词
hydroxocobalamin; cyanide; sodium thiosulfate; sodium nitrite; antidote; poison center; THIOSULFATE;
D O I
10.1097/MJT.0b013e31824ea656
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sodium nitrite and sodium thiosulfate are common cyanide antidotes. Hydroxocobalamin was approved for use in the United States in 2006. Our objective was to determine the frequency of antidote use as reported to the US poison centers from 2005 to 2009 and describe which antidotes were used in critically ill cyanide toxic patients. We performed a retrospective review over 5 years (2005-2009) from 61 US poison centers. We identified all cyanide-exposed cases that received a cyanide antidote. Variables collected included demographics, gastric decontamination, antidote used, predefined serious clinical effects (hypotension, cardiac arrest, respiratory arrest, and coma), and predefined serious therapies (cardiopulmonary resuscitation, vasopressors, atropine, anticonvulsant, antidysrhythmic, and intubation/ventilation). One trained abstractor abstracted each chart to a standardized electronic form. Another investigator audited 20% of the charts. Kappa values were calculated. One hundred sixty-five exposures were identified. Mean age was 42 years (range, 3-93 years). Seventy-one percent were male. Exposures were 27% ingestion and 53% inhalation. Thirty-two percent of the ingestions were suicide attempts. Twenty percent (32 of 157) of all cases died. Over all years reported, hydroxocobalamin was administered to 29% (45 of 157) of patients, sodium nitrite to 25%, and sodium thiosulfate to 46%. Hydroxocobalamin use increased from 24% to 54% from 2007 to 2009, respectively (P = 0.024). Sodium thiosulfate use decreased from 73% to 31% (P = 0.002) and sodium nitrite use decreased from 26% to 14% (P = 0.39). The proportion of cases with serious clinical effects that received hydroxocobalamin increased each year, and the proportion that received other antidotes decreased. Hydroxocobalamin was also administered more often in cases that required serious therapies and increased each year. Hydroxocobalamin use for cyanide toxicity increased each year as reported to the US poison centers. Reported use of sodium thiosulfate and sodium nitrite decreased over the same years. In addition, hydroxocobalamin was used more often each year in critically ill cyanide toxic patients than were sodium nitrite or sodium thiosulfate.
引用
收藏
页码:244 / 249
页数:6
相关论文
共 50 条
  • [1] Risk of oxalate nephropathy with the use of cyanide antidote hydroxocobalamin in critically ill burn patients
    Matthieu Legrand
    Thibault Michel
    Michel Daudon
    Mourad Benyamina
    Axelle Ferry
    Sabri Soussi
    Véronique Maurel
    Maïte Chaussard
    Marc Chaouat
    Maurice Mimoun
    Jérôme Verine
    Vincent Mallet
    Alexandre Mebazaa
    Intensive Care Medicine, 2016, 42 : 1080 - 1081
  • [2] Safety of hydroxocobalamin use in the Prehospital setting as an antidote for smoke inhalation associated cyanide poisoning
    Baud, F.
    Borron, S.
    ANNALS OF EMERGENCY MEDICINE, 2006, 48 (04) : S55 - S55
  • [3] Risk of oxalate nephropathy with the use of cyanide antidote hydroxocobalamin in critically ill burn patients
    Legrand, Matthieu
    Michel, Thibault
    Daudon, Michel
    Benyamina, Mourad
    Ferry, Axelle
    Soussi, Sabri
    Maurel, Veronique
    Chaussard, Maite
    Chaouat, Marc
    Mimoun, Maurice
    Verine, Jerome
    Mallet, Vincent
    Mebazaa, Alexandre
    INTENSIVE CARE MEDICINE, 2016, 42 (06) : 1080 - 1081
  • [4] Interference of the cyanide antidote hydroxocobalamin with carboxyhemoglobin measurements should not limit clinical use in suspected or confirmed cyanide poisoning
    Borron, Stephen W.
    Uhl, Wolfgang
    Nolting, Arno
    Hostalek, Ulrike
    Serono, Merck
    ANNALS OF EMERGENCY MEDICINE, 2007, 50 (05) : 624 - 625
  • [5] Approval Status and Regulatory Actions for Radiopharmaceuticals in the United States and Japan
    Nobuyuki Hanamura
    Atsushi Aruga
    Therapeutic Innovation & Regulatory Science, 2014, 48 : 635 - 643
  • [6] Regulatory Considerations for the Approval of Analgesic Drugs for Cattle in the United States
    Smith, Emily R.
    Modric, Sanja
    VETERINARY CLINICS OF NORTH AMERICA-FOOD ANIMAL PRACTICE, 2013, 29 (01) : 1 - +
  • [7] United States Regulatory Approval of Topical Treatments for Dry Eye
    Cui, David
    Saldanha, Ian J.
    Li, Gavin
    Mathews, Priya M.
    Lin, Michael X.
    Akpek, Esen K.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2024, 258 : 14 - 21
  • [8] Approval Status and Regulatory Actions for Radiopharmaceuticals in the United States and Japan
    Hanamura, Nobuyuki
    Aruga, Atsushi
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (05) : 635 - 643
  • [9] A Comparison of Regulatory Approval Time for Ophthalmic Devices in the United States and Japan
    Parikh, Ravi
    Gopal, Anand
    Teng, Christopher
    Del Priore, Lucian
    Ross, Joseph S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [10] Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis
    Anand, Priyanka
    Schneeweiss, Sebastian
    Mostaghimi, Arash
    Schneeweiss, Maria. C. C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (05) : 567 - 576